When was Deep Genomics founded?

Deep Genomics was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Deep Genomics located?

Deep Genomics is headquartered in Toronto, Canada.

How many employees does Deep Genomics have?

As of Apr 30, 2026, the latest employee count at Deep Genomics is 108.

Is Deep Genomics a funded company?

Deep Genomics is a funded company, having raised a total of $238M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 18, 2015.

When was the latest funding round of Deep Genomics?

Deep Genomics' latest funding was a $***** Series C round on Jul 28, 2021, with participation from 8 investors.

Where does Deep Genomics rank among its competitors?

Deep Genomics ranks 9th amongst 788 active competitors, of which 212 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Deep Genomics?

Deep Genomics' top competitors include Denali Therapeutics, Caris Life Sciences and Geneoscopy. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Deep Genomics - 2026 Company Profile, Team, Funding & Competitors

Company Details

AI-powered platform for RNA biology to accelerate genetic therapy discovery. It focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions. Its offers proprietary AI platform including the flagship model BigRNA that uses machine learning to analyze vast RNA biology data, identify therapeutic targets, and evaluate potential therapeutic candidates efficiently than traditional approaches. The technology helps accelerate early stages of drug discovery and design of RNA-based therapies.

Website: www.deepgenomics.com/
Social
Email ID: *****@deepgenomics.com

Key Metrics

Founded Year

2014

Location

Toronto, Canada

Stage

Series C

Total Funding

$238M in 4 rounds

Latest Funding Round

Series C, Jul 28, 2021, $*****

Investors

Khosla Ventures & 17 more

Ranked

9^th among 788 active competitors

Employee Count

108 as on Apr 30, 2026

Similar Companies

Innovaccer & 3389 more

View Deep Genomics' full profile

Deep Genomics has raised a total funding of $238M over 4 rounds. Its first funding round was on Nov 18, 2015. Its latest funding round was a Series C round on Jul 28, 2021 for $*****. 8 investors participated in its latest round. Deep Genomics has 18 institutional investors.

Here is the list of recent funding rounds of Deep Genomics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 28, 2021	8310096	Series C	3425929	9034794	7775205	9002596
Jan 07, 2020	4967892	Series B	5494125	7951133	6734695	Amplitude & 4 more
Sep 25, 2017	1045324	Series A	7362178	7957823	Khosla Ventures	True Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Deep Genomics's funding rounds and investors

The founders of Deep Genomics are Brendan Frey, Hui Yuan Xiong and Hannes Bretschneider.

Here are the details of Deep Genomics' key team members:

Brendan Frey: Co-Founder & Chief Innovation Officer of Deep Genomics.
Contact Info: 1 email address
Hui Yuan Xiong: Former Co-Founder of Deep Genomics.
Hannes Bretschneider: Co-Founder and Chief Software Architect of Deep Genomics.

View details of Deep Genomics's Founder profiles and Board Members

Deep Genomics' employee count trend

Deep Genomics has 108 employees as of Apr 26. Here is Deep Genomics's employee count trend over the years:

Uncover Deep Genomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Deep Genomics include Denali Therapeutics, Caris Life Sciences and Geneoscopy. Here is the list of Top 10 competitors of Deep Genomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
3rd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
4th	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
5th	Stoke Therapeutics 2014, Bedford (United States), Public	Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing	$131M	RTW Investments, Apple Tree Partners & 5 others	67/100
6th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Orbimed, Novartis & 10 others	66/100
7th	Unilabs 2000, Geneva (Switzerland), Acquired	Provider of diagnostics services company	-	Digital Pharma Lab, Nordic Capital & 1 others	65/100
8th	ACT Genomics 2014, Taipei (Taiwan), Acquired	Clinical and research services in genomics for cancer	$20.5M	Hotung Investment Holdings, CLSA Capital Partners ... & 9 others	64/100
9th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	Fidelity Investments, Deep Learning & 16 others	63/100
10th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Ironwood Capital, Enhanced Capital & 3 others	63/100